TxCell Enrolls First Patient for Phase IIb Crohn’s Disease Study
News
TxCell SA, a biotechnology company specializing in developing novel immunotherapies for severe chronic inflammatory and autoimmune diseases, has just announced the enrollment and dosing of the first patient in the ... Read more